Inhibition of human recombinant T-type calcium channels by N-arachidonoyl 5-HT

British Journal of Pharmacology

Volumn 167, Issue 5, 2012, Pages 1076-1088

  Gilmore, Andrew J ^a   Heblinski, Marika ^c   Reynolds, Aaron ^a   Kassiou, Michael ^a,b   Connor, Mark ^a,c  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c MACQUARIE UNIVERSITY   (Australia)

Author keywords

acyl amino acid; anandamide; arachidonoyl amino acid; NA 5HT; NA serotonin; nociception; T type calcium channel

Indexed keywords

CALCIUM CHANNEL T TYPE; N ARACHIDONOYLSEROTONIN; RECOMBINANT CALCIUM CHANNEL T TYPE; RECOMBINANT PROTEIN; SEROTONIN DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CURRENT; CELL STRAIN HEK293; CONTROLLED STUDY; DEPOLARIZATION; ELECTROPHYSIOLOGY; HUMAN; HUMAN CELL; HYPERPOLARIZATION; KINETICS; PATCH CLAMP; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEADY STATE; VOLTAGE CLAMP; WHOLE CELL;

ANALGESICS; ARACHIDONIC ACIDS; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, T-TYPE; HEK293 CELLS; HUMANS; RECOMBINANT PROTEINS; SEROTONIN;

EID: 84867310203     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02047.x     Document Type: Article

References (51)

1. Alexander SPH, Mathie A, Peters JA, (2011). Guide to receptors and channels (GRAC), 5th edition. Br J Pharmacol 164 (Suppl. 1): S1-S324.
2. Barbara G, Alloui A, Nargeot J, Lory P, Eschalier A, Bourinet E, et al,. (2009). T-type calcium channel inhibition underlies the analgesic effects of the endogenous lipoamino acids. J Neurosci 29: 13106-13114.
3. 2+ channel antagonists mibefradil and pimozide inhibit cell growth via different cytotoxic mechanisms. Mol Pharmacol 62: 210-219. (Pubitemid 34804099)
4. Bifulco M, Laezza C, Valenti M, Ligestri A, Portella G, Di Marzo V, (2004). A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J 18: 1606-1608. (Pubitemid 39561648)
5. Bisogno T, Melck D, De Petrocellis L, Yu M, Bobrov MY, Gretskaya NM, et al,. (1998). Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem Biophys Res Comm 248: 515-522. (Pubitemid 28404452)
6. 1 cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem J 351: 817-824.
7. V3.2 T-type calcium channel gene in sensory neurons demonstrates its major role in nociception. EMBO J 24: 315-324. (Pubitemid 40216136)
8. Burstein SH, Rossetti RG, Yagen B, Zurier RB, (2000). Oxidative metabolism of anandamide. Prostaglandins Other Lipid Mediat 61: 29-41. (Pubitemid 30216487)
9. Chemin J, Monteil A, Perez-Reyes E, Nargeot J, Lory P, (2001). Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J 20: 7033-7040. (Pubitemid 34062295)
10. Chemin J, Nargeot J, Lory P, (2007). Chemical determinants involved in anandamide-induced inhibition of T-type calcium channels. J Biol Chem 282: 2314-2323. (Pubitemid 47076786)
11. Connor M, Vaughan CW, Vandenberg R, (2010). N-Acyl amino acids and N-acyl neurotransmitter conjugates: neuromodulators and probes for new drug targets. Br J Pharmacol 160: 1857-1871.
12. Costa B, Bettoni I, Petrosino S, Comelli F, Giagnoni G, Di Marzo V, (2010). The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl- serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice. Pharm Res 61: 537-546.
13. 2+ channel gene family. Circ Res 83: 103-109. (Pubitemid 28322104)
14. V3.1c, a T-type calcium channel from human brain. FEBS Lett 466: 54-58. (Pubitemid 30050682)
15. D'Argenio G, Valenti M, Scaglione G, Cosenza V, Sorrentini I, Di Marzo V, (2006). Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 20: 568-570. (Pubitemid 46671252)
16. Di Marzo V, Capasso R, Matias I, Aviello G, Petrosino S, Borrelli F, et al,. (2008). The role of endocannabinoids in the regulation of gastric emptying: alterations in mice fed a high fat diet. Br J Pharmacol 153: 1271-1280.
17. Docherty RJ, Yeats JC, Piper AC, (1997). Capsazepine block of voltage-activated calcium channels in adult dorsal root ganglion neurones in culture. Br J Pharmacol 121: 1461-1467. (Pubitemid 27317561)
18. Edington AR, McKinzie AA, Reynolds AJ, Kassiou M, Ryan RM, Vandenberg RJ, (2009). Extracellular loops 2 and 4 of GLYT2 are required for N-arachidonyl-glycine inhibition of glycine transport. J Biol Chem 284: 36424-36430.
19. Fowler CJ, Tiger G, Lopez-Rodriguez ML, Viso A, Ortega-Gutierrez S, Ramos JA, (2003). Inhibition of fatty acid aminohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogs of arachidonoyl-serotonin. J Enzyme Inhib Med Chem 18: 225-231. (Pubitemid 36827034)
20. Frazier CJ, Serrano JR, George EG, Yu X, Viswanathan A, Perez-Reyes E, et al,. (2001). Gating kinetics of the α1I T-type calcium channel. J Gen Physiol 118: 457-470. (Pubitemid 33064285)
21. Giordanetto F, Knerr L, Wallberg A, (2011). T-type calcium channel inhibitors: a patent review. Expert Opin Ther Patents 21: 85-191.
22. V3.3: insights into prepulse facilitation. Biophys J 83: 229-241. (Pubitemid 34694734)
23. Guo J, Williams DJ, Ikeda SR, (2008). N-arachidonyl serine, a putative endocannabinoid, alters the activation of N-type calcium channels in sympathetic neurons. J Neurophysiol 100: 1147-1151.
24. Hamill OP, Marty A, Neher E, Sakmann B, Sigworth FJ, (1981). Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch 391: 85-100. (Pubitemid 11012976)
25. Heblinski M, Connor M, (2012). Agonist regulation of 5HT1B receptor signaling. Proc 32nd Aust Neurosci Soc, p 77.
26. Huang SM, Bisogno T, Petros TJ, Chang S-Y, Zavitsanos PA, Zipkin RE, et al,. (2001). Identification of a new class of molecules, the arachidonyl amino acids, and characterization of one member that inhibits pain. J Biol Chem 276: 42639-42634.
27. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, de Petrocellis L, Fezza F, et al,. (2002). An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid receptors. Proc Natl Acad Sci U S A 99: 8400-8405. (Pubitemid 34651064)
28. Jacobsson SOP, Wallin T, Fowler CJ, (2001). Inhibition of rat C6 glioma cell proliferation by endogenous and synthetic cannabinoids. Relative involvement of cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 299: 951-959. (Pubitemid 33104965)
29. Jonsson K-O, Vandevoorde S, Lambert DM, Tiger G, Fowler CJ, (2001). Effects of homologs and analogs of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol 133: 1263-1275. (Pubitemid 32783487)
30. Kim D, Park D, Choi S, Lee S, Sun M, Kim C, et al,. (2003). Thalamic control of visceral nociception mediated by T-type calcium channels. Science 302: 117-119. (Pubitemid 37210701)
31. Maione S, de Petrocellis L, de Novellis V, Schiano Moriello A, Petrosino S, Palazzo E, et al,. (2007). Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol 150: 766-781. (Pubitemid 46440215)
32. Marinelli S, Di Marzo V, Florenzano F, Fezza F, Viscomi MT, van der Stelt M, et al,. (2007). N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 32: 298-308. (Pubitemid 46106937)
33. de Novellis V, Palazzo E, Rossi F, De Petrocellis L, Petrosino S, Guida F, et al,. (2008). The analgesic effect of N-arachidonoyl-serotonin, a FAAH inhibitor and TRPV1 receptor antagonist, associated with changes in rostral ventromedial medulla and locus coeruleus cell activity in rats. Neuropharmacology 55: 1105-1113.
34. de Novellis V, Vita D, Gatta L, Luongo L, Bellini G, De Chiaro M, et al,. (2011). The blockade of the transient receptor potential type 1 and fatty amide hydrolase decreases symptoms and central sequelae in the medial prefrontal cortex of neuropathic rats. Mol Pain 7: 7.
35. Panner A, Wurster RD, (2006). T-type calcium channels and tumor proliferation. Cell Calcium 40: 253-259. (Pubitemid 43942305)
36. Park C, Kim JH, Yoon BE, Choi EJ, Lee CJ, Shin HS, (2010). T-type channels control the opioidergic descending analgesia at the low threshold-spiking GABAergic neurons in the periaqueductal gray. Proc Natl Acad Sci U S A 107: 14857-14862.
37. Perez-Reyes E, (2003). Molecular physiology of low-voltage-activated T-type calcium channels. Physiol Rev 83: 117-161. (Pubitemid 36459879)
38. 9-Tetrahydrocannabinol and cannabidiol. J Biol Chem 283: 16124-16134.
39. Ross HR, Gilmore AJ, Connor M, (2009). Inhibition of human recombinant T-type calcium channels by the endocannabinoid arachidonyl dopamine. Br J Pharm 156: 740-750.
40. Shin H-S, Cheong E-J, Choi S, Lee J, Na HS, (2008). T-type calcium channels as therapeutic targets in the nervous system. Curr Opin Pharmacol 8: 33-41.
41. Succar R, Mitchell VA, Vaughan CW, (2007). Actions of N-arachidonyl-glycine in a rat inflammatory pain model. Mol Pain 3: 24.
42. Suplita RL II, Farthing JN, Gutierrez T, Hohmann AG, (2005). Inhibition of fatty-acid amide hydrolase enhances cannabinoid stress-induced analgesia: sites of action in the dorsal periaqueductal grey and rostral ventromedial medulla. Neuropharmacology 49: 1201-1209. (Pubitemid 41608644)
43. Suplita RL II, Gutierrez T, Fegley D, Piomelli D, Hohmann AG, (2006). Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. Neuropharmacology 50: 372-379. (Pubitemid 43184365)
44. 1g. J Gen Physiol 124: 225-238. (Pubitemid 39244523)
45. Traboulsie A, Chemin J, Chevalier M, Quignard J-F, Nargeot J, Lory P, (2007). Subunit-specific modulation of T-type calcium channels by zinc. J Physiol 578: 159-171. (Pubitemid 44971117)
46. Verhoeckx KCM, Voortman T, Balvers MGJ, Hendriks HFJ, Wortelboer HM, Witkamp RF, (2011). Presence formation and putative biological activities of N-acyl serotonins, a novel class of fatty-acid derived mediators, in the intestinal tract. Biochem Biophys Acta 1811: 578-586.
47. Vuong LAQ, Mitchell VA, Vaughan CW, (2008). Actions of N-arachidonyl-glycine in a rat neuropathic pain model. Neuropharmacology 54: 189-193.
48. Wiles AL, Pearlman RJ, Rosvall M, Aubrey K, Vandenberg RJ, (2006). N-arachidonyl glycine inhibits the glycine transporter, GLYT2a. J Neurochem 99: 781-786. (Pubitemid 44583437)
49. Yang Z, Aubrey KR, Alroy I, Harvey RJ, Vandenberg RJ, Lynch JW, (2008). Subunit-specific modulation of glycine receptors by cannabinoids and N-arachidonyl-glycine. Biochem Pharmacol 76: 1014-1023.
50. Yevenes GE, Zeilhofer HU, (2011). Molecular sites for the positive allosteric modulation of glycine receptors by endocannabinoids. PLoS ONE 6: e23886.
51. Zhang Y, Cribbs L, Satin J, (2000). Arachidonic acid modulation of α1H, a cloned human T-type calcium channel. Am J Physiol Heart Circ Physiol 278: H184-H193. (Pubitemid 30101870)